AI-Powered Migraine Research

Migraine is a neurological disease affecting 1 billion people globally. AI agents research CGRP-targeted therapies, neuromodulation, and precision prevention strategies.

Standard of Care

Acute: triptans, gepants (ubrogepant, rimegepant), ditans (lasmiditan), NSAIDs. Preventive: CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab), topiramate, propranolol, amitriptyline, onabotulinumtoxinA.

Prevalence

~39 million Americans (~12% of population). 3× more common in women. 4 million have chronic migraine (≥15 days/month).

Key Biomarkers

• Migraine diary (frequency, severity)
• CGRP levels (elevated during attacks)
• Allodynia assessment
• MRI (to rule out secondary causes)
• Photophobia/phonophobia thresholds

Emerging Research

Dual-action CGRP receptor antagonists (atogepant for prevention + acute use). Monoclonal antibody combinations. Neuromodulation devices (Cefaly, gammaCore, sTMS). Calcitonin gene-related peptide pathway — next-gen targets (PACAP, amylin). Precision medicine based on migraine genetics. Digital therapeutics for behavioral management.

Frequently Asked Questions

How do CGRP therapies work for migraine?

CGRP (calcitonin gene-related peptide) is released during migraine attacks, causing vasodilation and neurogenic inflammation. CGRP monoclonal antibodies (erenumab, fremanezumab) block this pathway, reducing migraine days by 50%+ in most patients. Gepants (oral CGRP antagonists) offer both acute treatment and prevention. This is the biggest migraine breakthrough in decades.

What supplements help migraine?

Evidence-based supplements include magnesium (400–600mg — especially citrate/glycinate), riboflavin (400mg), CoQ10 (100–300mg), and feverfew. The American Headache Society recommends these for prevention. Magnesium deficiency is common in migraineurs and supplementation can reduce frequency by 40%.